|
|
Sinopharm Group Co., Ltd. won the Best IPO of year 2009 in ‘IFR Asia’
|
|
Feb 10th, 2010, the world famous magazine ‘International Finance Review (Asia)’ (IFR Asia) held its 2009 Annual Award Ceremony in Hong Kong, the IPO and market listing project of H shares of Sinopharm Group Co., Ltd. (01099, HK) won the best IPO of year 2009, this was another greatest honour earned by Chinese enterprise, since before, Sinopharm Group Co., Ltd. also won the best IPO of year 2009 in Finance Asia.
Sinopharm Group Co., Ltd. is a key subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM), and was officially launched in HK stock market on Sep 23rd, 2009, with a financing size of 10.04 billion HKD This makes the highest amount of global financing in the pharmaceutical projects since entering 21st century. It breaks the record of the offering by Chinese state-owned enterprises in the overseas stock market and the IPO is with the highest evaluation issued overseas by Chinese state-owned enterprises, which established the benchmark for values within the Chinese pharmaceutical field. Till the close on Feb 28th, 2010, the market value of Sinopharm Group Co., Ltd. was 33.95HKD/share, 112% increase to issue price, total market value is 76.7 billion HKD. It is the largest listed company in Chinese pharmaceutical field, ranked 3rd place in the global medicine distributions (the first two are US MACKESSON CORP and CARDINAL HEALTH respectively).
IFR Asia belongs to the world largest financial intelligence information provider Thomson Reuters, it carries out annual strict selection of the Asia capital market insurance and securities underwriting, the Best IPO Award is considered to be the extreme appreciation to the performance and achievement within Asian financing market by the new listed company in the current year. The winners usually have outstanding performance in its issue terms, investor structure and capital strengthening effect, etc. Under the influence of the global financial crisis, it has great significance for Sinopharm Group Co., Ltd. to have this award. It does not just state the importance of Chinese state-owned enterprises could get to in the international capital market, but also creates the highest offering valuation for Chinese state-owned enterprises in overseas market. With considerable strength and advantage, Sinopharm Group Co., Ltd. will seize the opportunity, go ahead with its advantages, to create values for the investors, and to make active contributions to the development of Chinese pharmaceutical market. [Sinopharm Group Co., Ltd. Submits]
|
|
|
 【Print】  【close】 |
|
|
| |